High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein

Brain Tumor Pathology

Volumn 28, Issue 2, 2011, Pages 107-114

  Ikota, Hayato ^a   Nobusawa, Sumihito ^a   Tanaka, Yuko ^a   Yokoo, Hideaki ^a   Nakazato, Yoichi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Brain tumors; Immunohistochemistry; Isocitrate dehydrogenase 1; Tissue microarray

Indexed keywords

ARGININE; ENZYME ANTIBODY; HISTIDINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 1 ANTIBODY; MITOCHONDRION ANTIBODY; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ACINAR CELL; ADRENAL CORTEX; ANTIBODY SPECIFICITY; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CELL NUCLEUS; CHOROID PLEXUS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; CROSS REACTION; CYTOPLASM; ENZYME LOCALIZATION; GLIOBLASTOMA; GRANULOSA CELL; HEART MUSCLE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; LARGE INTESTINE; LIVER CELL; MAJOR CLINICAL STUDY; MENINGIOMA; MITOCHONDRION; OLIGODENDROGLIOMA; ORGAN; PANCREAS DUCT; PRIMARY TUMOR; SALIVARY GLAND; STOMACH FUNDUS; STOMACH GLAND;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MUTANT PROTEINS; OLIGODENDROGLIOMA; ORGAN SPECIFICITY; STAINING AND LABELING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052764895     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-010-0016-y     Document Type: Article

References (22)

1. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
2. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007
3. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474
4. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
5. Kloosterhof NK, Bralten LB, Dubbink HJ et al (2010) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. doi:10.1016/S1470-2045(10)70053-X
6. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
7. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347
8. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
9. Capper D, Zentgraf H, Balss J et al (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601
10. Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254
11. Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847 (Pubitemid 28331029)
12. Ikota H, Kinjo S, Yokoo H, Nakazato Y (2006) Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 111:475-482
13. Capper D, Sahm F, Hartmann C et al (2010) Application of mutant IDH1 antibody to differentiate diffuse glioma from non-neoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34:1199-1204
14. Camelo-Piragua S, Jansen M, Ganguly A et al (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119:509-511
15. Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumours of the central nervous system. IARC, Lyon
16. Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602
17. Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11
18. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932-941
19. Mardis ER, Ding L, Dooling DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066
20. Gaal J, Burnichon N, Korpershoek E et al (2010) Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95:1274-1278
21. Kang MR, Kim MS, Oh JE et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353-355
22. Sjöblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274 (Pubitemid 44571966)